Healthtech Solutions, Inc./UT

$ Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000126246323000045 Filed on June 28, 2023

Income Statement

Concept	2023 Q2	2022 Q4	2022

Balance Sheet

Concept	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$97.59K	$97.59K
YoY Change	1272.57%	875.9%
Cash & Equivalents	$97.59K	$97.59K
Short-Term Investments
Other Short-Term Assets	$681.1K	$681.1K
YoY Change	393.53%	386.48%
Inventory	$403.6K	$403.6K
Prepaid Expenses	$305.6K
Receivables	$1.239M	$1.239M
Other Receivables	$42.85K	$42.85K
Total Short-Term Assets	$2.464M	$2.464M
YoY Change	686.84%	694.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$83.33K	$83.33K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$110.0K	$110.0K
YoY Change	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$288.8K	$288.8K
YoY Change	162.52%	162.52%
TOTAL ASSETS
Total Short-Term Assets	$2.464M	$2.464M
Total Long-Term Assets	$288.8K	$288.8K
Total Assets	$2.752M	$2.752M
YoY Change	550.53%	555.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.460M	$2.460M
YoY Change	235.29%	237.01%
Accrued Expenses	$375.5K	$375.5K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$2.992M	$2.992M
YoY Change	787.92%	779.88%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.827M	$5.827M
YoY Change	444.27%	444.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.827M	$5.827M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$5.827M	$5.506M
YoY Change	444.27%	414.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$13.68M
YoY Change	29.73%
Common Stock	$72.22K
YoY Change	7.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.753M	-$2.753M
YoY Change
Total Liabilities & Shareholders Equity	$2.752M	$2.752M
YoY Change	550.53%	555.33%

Cashflow Statement

Concept	2023 Q2	2022 Q4	2022

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001307624
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021	hltt	Debt Conversion Original Debt Amount DebtConversionOriginalDebtAmount		usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
CY2022	hltt	Issuance Of Common Stock IssuanceOfCommonStock		usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022	hltt	Advances To Divested Subsidiary AdvancesToDivestedSubsidiary		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	0-51012
CY2022	dei	Entity Registrant Name EntityRegistrantName	HEALTHTECH SOLUTIONS, INC./UT
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	UT
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2528660
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	181 Dante Avenue
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Tuckahoe
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10707
CY2022	dei	City Area Code CityAreaCode	844
CY2022	dei	Local Phone Number LocalPhoneNumber	926-3399
CY2022	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value per share
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	6953193	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96131606	shares
CY2022	dei	Auditor Name AuditorName	Prager Metis CPA’s LLC
CY2022	dei	Auditor Firm AuditorFirmId	273
CY2022	dei	Auditor Location AuditorLocation	New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97588	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7105	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1238509	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	403595	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	305587	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	137997	usd
CY2022Q4	us-gaap	Loans Receivable Held For Sale Amount LoansReceivableHeldForSaleAmount	0	usd
CY2021Q4	us-gaap	Loans Receivable Held For Sale Amount LoansReceivableHeldForSaleAmount	168000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	42853	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2022Q4	hltt	Operating Lease Right Of Use Asset Current OperatingLeaseRightOfUseAssetCurrent	375483	usd
CY2021Q4	hltt	Operating Lease Right Of Use Asset Current OperatingLeaseRightOfUseAssetCurrent	0	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2463615	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	313102	usd
CY2022Q4	hltt	Due From Affiliate Noncurrent Asset DueFromAffiliateNoncurrentAsset	110000	usd
CY2021Q4	hltt	Due From Affiliate Noncurrent Asset DueFromAffiliateNoncurrentAsset	110000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83333	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	95439	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	288772	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	110000	usd
CY2022Q4	us-gaap	Assets Assets	2752387	usd
CY2021Q4	us-gaap	Assets Assets	423102	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2460179	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	733743	usd
CY2022Q4	hltt	Due To Related Party Current DueToRelatedPartyCurrent	1373750	usd
CY2021Q4	hltt	Due To Related Party Current DueToRelatedPartyCurrent	0	usd
CY2022Q4	hltt	Loans From Shareholders LoansFromShareholders	1617844	usd
CY2021Q4	hltt	Loans From Shareholders LoansFromShareholders	336921	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	375483	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5827256	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1070665	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5827256	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1070665	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	110	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	110	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72215933	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72215933	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66965933	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66965933	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	72216	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	66966	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10858036	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9833286	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13683565	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10547924	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2753203	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-647563	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-321666	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	0	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3074869	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-647563	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2752387	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	423102	usd
CY2022	us-gaap	Revenues Revenues	1687691	usd
CY2021	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	123857	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2022	us-gaap	Gross Profit GrossProfit	1563834	usd
CY2021	us-gaap	Gross Profit GrossProfit	0	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2844277	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1902438	usd
CY2022	hltt	General And Administrativerelated Party GeneralAndAdministrativerelatedParty	255000	usd
CY2021	hltt	General And Administrativerelated Party GeneralAndAdministrativerelatedParty	2595132	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1771203	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	159772	usd
CY2022	hltt	Research And Development Related Party ResearchAndDevelopmentRelatedParty	72000	usd
CY2021	hltt	Research And Development Related Party ResearchAndDevelopmentRelatedParty	322000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	78660	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25926	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	5021140	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	5005268	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3457306	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-5005268	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2021	us-gaap	Interest Expense InterestExpense	367144	usd
CY2022	hltt	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	0	usd
CY2021	hltt	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	2933735	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-0	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3300879	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3457306	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8306147	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3457306	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8306147	usd
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	0	usd
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-668960	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	0	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-134111	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-803071	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3457306	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-9109218	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-413721	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3043585	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9109218	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68068672	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68068672	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29430180	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29430180	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-562597	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3229028	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1792500	usd
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	3998167	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	4558	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9109217	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-647563	usd
CY2022	hltt	Proceeds Of Loans From Shareholders ProceedsOfLoansFromShareholders	1280922	usd
CY2021	hltt	Proceeds Of Loans From Shareholders ProceedsOfLoansFromShareholders	336921	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	707500	usd
CY2022	hltt	Issuance Of Common Stock In Satisfaction Of Account Payable IssuanceOfCommonStockInSatisfactionOfAccountPayable	187500	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	135000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3457306	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3074869	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3457306	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-9109218	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	668960	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3457306	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-8440258	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	41993	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25926	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36667	usd
CY2022	hltt	Noncash Compensation NoncashCompensation	707500	usd
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	367144	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	135000	usd
CY2021	hltt	Issuance Of Common Stock IssuanceOfCommonStock	3229028	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	70155	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	175387	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-134111	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-0	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-2933735	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-105167	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	128059	usd
CY2022	hltt	Increase Decrease In Prepaid Commissions IncreaseDecreaseInPrepaidCommissions	104756	usd
CY2021	hltt	Increase Decrease In Prepaid Commissions IncreaseDecreaseInPrepaidCommissions	-0	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	473750	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1413896	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-0	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	42853	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-0	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1656503	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	653575	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2564189	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1224798	usd
CY2021	hltt	Advances To Divested Subsidiary AdvancesToDivestedSubsidiary	913071	usd
CY2022	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	-0	usd
CY2021	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	168000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1081071	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	50000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1373750	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2022	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	0	usd
CY2021	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	4558	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1792500	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2654672	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2183979	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	90483	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-121891	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7105	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	128996	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97588	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7105	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	61	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	hltt	Acquired Noncontrolling Interest For Issuance Of Common Stock AcquiredNoncontrollingInterestForIssuanceOfCommonStock	187500	usd
CY2021	hltt	Acquired Noncontrolling Interest For Issuance Of Common Stock AcquiredNoncontrollingInterestForIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zY47VWpQdohd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_86B_zMttiveakZ13">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Management makes these estimates using the best information available at the time the estimates are made; however, actual results could differ from those estimates. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13683565	usd
CY2022Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	137432	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	199354	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	274396	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	473750	usd
CY2021Q4	us-gaap	Inventory Gross InventoryGross	0	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	70155	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	-0	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	403595	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	70155	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P23M
CY2022Q3	us-gaap	Area Of Land AreaOfLand	10800	sqft
CY2022Q3	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-12-31
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	31538	usd
CY2022	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.065	pure
CY2022Q4	hltt	Office And Warehouse Lease OfficeAndWarehouseLease	689723	usd
CY2021Q4	hltt	Office And Warehouse Lease OfficeAndWarehouseLease	0	usd
CY2022Q4	hltt	Right Of Use Assets Accumulated Amortization RightOfUseAssetsAccumulatedAmortization	314240	usd
CY2021Q4	hltt	Right Of Use Assets Accumulated Amortization RightOfUseAssetsAccumulatedAmortization	-0	usd
CY2022Q4	hltt	Right Of Use Assets Net RightOfUseAssetsNet	375483	usd
CY2021Q4	hltt	Right Of Use Assets Net RightOfUseAssetsNet	0	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	388862	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	0	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	388862	usd
CY2022Q4	us-gaap	Other Borrowings OtherBorrowings	1617844	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	15000000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.25
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8962500	shares
CY2021Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1792500	usd
CY2021	hltt	Common Stock For Services Shares CommonStockForServicesShares	4975000	shares
CY2021	hltt	Common Stock For Services Value CommonStockForServicesValue	3229028	usd
CY2022	hltt	Common Stock For Services Shares CommonStockForServicesShares	2750000	shares
CY2022	hltt	Common Stock For Services Value CommonStockForServicesValue	707500	usd
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3507164	shares
CY2021Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.14
CY2021Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	16910	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	15000000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.25
CY2022Q3	hltt	Value Of Stock Options Granted ValueOfStockOptionsGranted	135000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.050	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.110	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2021Q2	hltt	Settlement Upon Exchange For Common Stock SettlementUponExchangeForCommonStock	3296997	usd
CY2021Q2	hltt	Settlement Upon Exchange For Common Stock Principal SettlementUponExchangeForCommonStockPrincipal	681581	usd
CY2021Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2020Q4	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	337874	usd
CY2021Q1	hltt	Issued During Year IssuedDuringYear	25388	usd
CY2021Q1	hltt	Change In Fair Value ChangeInFairValue	-7215	usd
CY2021Q1	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	356047	usd
CY2021Q2	hltt	Change In Fair Value ChangeInFairValue	2940950	usd
CY2021Q2	hltt	Settlement Upon Exchange For Common Stock SettlementUponExchangeForCommonStock	3296997	usd
CY2021Q2	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.260	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.260	pure
CY2022	hltt	Net Deferred Tax Assets NetDeferredTaxAssets	0	pure
CY2021	hltt	Net Deferred Tax Assets NetDeferredTaxAssets	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.260	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.260	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3603089	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2742460	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3603089	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2742460	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3603089	usd
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Through 2036, the amount and utilization of any future net operating loss carry-forwards may be subject to limitations set forth by the Internal Revenue Code.

Files In Submission

Name	View Source	Status
hltt-20221231_def.xml	Edgar Link	unprocessable
hltt-20221231_lab.xml	Edgar Link	unprocessable
hltt-20221231_pre.xml	Edgar Link	unprocessable
0001262463-23-000045-index-headers.html	Edgar Link	pending
0001262463-23-000045-index.html	Edgar Link	pending
0001262463-23-000045.txt	Edgar Link	pending
0001262463-23-000045-xbrl.zip	Edgar Link	pending
ex21.htm	Edgar Link	pending
ex311.htm	Edgar Link	pending
ex312.htm	Edgar Link	pending
ex321.htm	Edgar Link	pending
ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hltt-20221231.xsd	Edgar Link	pending
hlttf10k12312022.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
hltt-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
hlttf10k12312022_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Healthtech Solutions, Inc./UT

2023 Q2 Form 10-K Financial Statement

#000126246323000045 Filed on June 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission